Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.
Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D. Quillien V, et al. Among authors: sanson m. Cancer Biomark. 2017 Dec 6;20(4):435-441. doi: 10.3233/CBM-170191. Cancer Biomark. 2017. PMID: 28800313 Free article.
Summary version of the Standards, Options and Recommendations for the management of adult patients with intracranial glioma (2002).
Frappaz D, Chinot O, Bataillard A, Ben Hassel M, Capelle L, Chanalet S, Chatel M, Figarella-Branger D, Guegan Y, Guyotat J, Hoang-Xuan K, Jouanneau E, Keime-Guibert F, Laforêt C, Linassier C, Loiseau H, Maire JP, Menei P, Rousmans S, Sanson M, Sunyach MP; FNCLCC; Neuro-oncology Group of the Fédération Nationale des Centres de Lutte Contre le Cancer; Association of French-speaking Neuro-oncologists. Frappaz D, et al. Among authors: sanson m. Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S73-83. doi: 10.1038/sj.bjc.6601087. Br J Cancer. 2003. PMID: 12915906 Free PMC article. No abstract available.
MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities.
Crinière E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, Everhard S, Mokhtari K, Polivka M, Delattre JY, Hoang-Xuan K, Thillet J, Sanson M. Crinière E, et al. Among authors: sanson m. J Neurooncol. 2007 Jun;83(2):173-9. doi: 10.1007/s11060-006-9320-0. Epub 2007 Jan 12. J Neurooncol. 2007. PMID: 17219056
Association of telomerase gene hTERT polymorphism and malignant gliomas.
Carpentier C, Lejeune J, Gros F, Everhard S, Marie Y, Kaloshi G, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Sanson M. Carpentier C, et al. Among authors: sanson m. J Neurooncol. 2007 Sep;84(3):249-53. doi: 10.1007/s11060-007-9378-3. Epub 2007 Apr 5. J Neurooncol. 2007. PMID: 17410334
No association of MDM2 SNP309 with risk of glioblastoma and prognosis.
El Hallani S, Marie Y, Idbaih A, Rodero M, Boisselier B, Laigle-Donadey F, Ducray F, Delattre JY, Sanson M. El Hallani S, et al. Among authors: sanson m. J Neurooncol. 2007 Dec;85(3):241-4. doi: 10.1007/s11060-007-9416-1. Epub 2007 Jun 14. J Neurooncol. 2007. PMID: 17568997
TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors.
Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Crinière E, Rodero M, Carpentier C, Paris S, Laigle-Donadey F, Ducray F, Hoang-Xuan K, Delattre JY. Idbaih A, et al. Among authors: sanson m. Cancer Genet Cytogenet. 2007 Sep;177(2):103-7. doi: 10.1016/j.cancergencyto.2007.06.010. Cancer Genet Cytogenet. 2007. PMID: 17854663
Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY. Idbaih A, et al. Among authors: sanson m. Brain Res. 2008 Mar 10;1198:16-20. doi: 10.1016/j.brainres.2008.01.027. Epub 2008 Jan 18. Brain Res. 2008. PMID: 18262501
431 results